VDVakaramoko Diaby

Vakaramoko Diaby

*This is an algorithmically generated author record based on publicly available information.

Vakaramoko Diaby has a total of 123 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Budget impact of aripiprazole once every 2 months long-acting injectable for adult patients with schizophrenia in the United States

    by Vakaramoko Diaby, Shubhram Pandey, Vassiki Sanogo, Reem Dhayan Almutairi, Yagyesh Kanoria, Soma S. Nag

    Schizophrenia is a chronic psychiatric disorder, affecting 1.1% of the adult population in 2020 in the United States. Antipsychotic treatment is commonly used in schizophrenia management to help reduce the likelihood of symptom recurrence and relapse. Aripiprazole once every month, a long-acting injectable antipsychotic formulation with an established efficacy and safety profile, is approved by the United States Food and Drug Administration as a maintenance treatment for schizophrenia. A new ready-to-use formulation of aripiprazole for administration once every 2 months (Ari 2MRTU) has been shown to have similar efficacy to aripiprazole once every month and was designed to improve medication adherence in order to provide antipsychotic treatment and prevent relapses. To estimate the financial impact of introducing Ari 2MRTU as a treatment option for adult patients diagnosed with schizophrenia in the United States. A cohort of adult patients with schizophrenia was selected from a hypothetical health plan of 1 million members. Treatment costs were modeled with a 3-year time horizon from 2024 to 2026, in scenarios with or without the addition of Ari 2MRTU. Inputs into the model included estimated current and projected market share of the available antipsychotics, expected uptake of Ari 2MRTU, as well as the acquisition, initiation, and administration costs, hospitalization costs, time on treatment, and patient member medication adherence. The budget impact was estimated as the difference in the annual cost for the total cohort for the current and new scenarios, the cost per member per month and per treated member per month. Deterministic sensitivity analyses were conducted to examine the extent to which the model results were affected by a change in individual all-input parameters. The total budget impact of Ari 2MRTU being adopted as an alternative maintenance monotherapy for treating eligible patients with schizophrenia from a hypothetical US health plan of 1 million members was estimated to be a saving of $26,998 over 3 years. This represented a per member per month saving of $0.001 and a per treated member per month saving of $0.11, whereas a sensitivity analysis indicated that these savings were sensitive to treatment adherence and the acquisition cost of the new formulation. The introduction of Ari 2MRTU as a maintenance treatment for adults with schizophrenia is expected to be cost neutral (with a modest saving) with respect to payer budgets in the United States. This merits consideration as is a potentially favorable option for patients who benefit from less frequent dosing.


  • Budget impact of aripiprazole once every 2 months long-acting injectable for adult patients with bipolar I disorder in the United States

    by Vakaramoko Diaby, Shubhram Pandey, Vassiki Sanogo, Reem Dhayan Almutairi, Yagyesh Kanoria, Soma S. Nag

    Bipolar disorder is a severe recurrent, episodic psychiatric condition with a worldwide prevalence of approximately 1%, affecting more than 5 million adults in the United States in 2020. A subtype, bipolar I disorder (BP-I), which accounts for approximately one-quarter of cases, is associated with impairments in psychosocial functioning and quality of life. Recommended treatment options include daily oral, or long-acting injectable, antipsychotics, including the aripiprazole once every month formulation, which has been shown to improve adherence compared with oral treatments. A new formulation of aripiprazole for administration once every 2 months ready to use (Ari 2MRTU) has been shown to have similar efficacy to monthly treatment, with only 6 doses annually. To estimate the financial impact of introducing the new formulation of aripiprazole as a treatment option for adults diagnosed with BP-I in the United States. A cohort of eligible patients with BP-I was selected from a hypothetical US health plan of 1 million members, and the treatment costs modeled with a 3-year time horizon, in scenarios with or without the addition of Ari 2MRTU. Inputs into the model included user-definable estimates of the current and projected market share of the available antipsychotics, forecast uptake of aripiprazole new formulation, acquisition, initiation, and administration costs, hospitalization costs, time on treatment, and patient adherence. The budget impact was estimated as the difference in the annual cost for the total cohort for the current and new scenarios, the cost per member per month, and the cost per treated member per month. Deterministic sensitivity analyses were also conducted to examine the extent to which the model results were affected by variations in individual input parameters. The total budget impact of introducing a formulation of Ari 2MRTU as maintenance monotherapy for treating a cohort of eligible patients with BP-I in the United States from a health plan of 1 million members was estimated to be $898,930 over 3 years, representing a per member per month cost saving of $0.025 and a per treated member per month cost saving of $2.43. The sensitivity analysis supports a modest reduction in budget, with the main driver being adherence with medication regimen. The introduction of Ari 2MRTU as a maintenance treatment for adults with BP-I is expected to have a neutral effect on payer budgets in the United States and is a potentially favorable option for patients who prefer less frequent dosing.


  • Open Access

    A bibliometric analysis and typology of drug pricing policies across the globe

    by Abdrahmane Berthe, Islam Eljilany, Amit Kulkarni, Vakaramoko Diaby

    Background: Limited research exists on pricing policies from a bibliometric and visualization perspective, and there is a lack of understanding of their typology. This study aims to address these gaps in knowledge and provide a deeper understanding of the research topics and development trends in this field. Methods: A bibliometric study was conducted on drug pricing approaches in healthcare literature, published between 2000 and June 2023. The literature was identified through an extensive search of healthcare databases and was then classified based on the year of publication, research topics, corresponding authors, location of corresponding authors, and journal titles. The citation data analysis was conducted using Bibliometrix, which consisted of descriptive, geographical, and time-series analyses and visualization. Results: Between 2000 and June 2023, 173 articles were disseminated across 98 distinct publication sources. During the analysis, we observed a significant and consistent rise in literature reports on drug pricing approaches in healthcare, especially in 2010. The research topics were distributed almost equally, discussing improvement or issues with drug pricing models and addressing drug pricing applications. Our analysis revealed that the top ten corresponding authors were responsible for 19% of the total articles, with those based in the United States being the most productive. Furthermore, the “Health Economics” journal ranked first among the top ten journals. These findings align with the overall publication trends of drug pricing methods reported in other fields. Conclusions: The current study offers a comprehensive overview of drug pricing techniques utilized in medicine through visualization and bibliometric techniques. Analysis of authors, journals, institutions, and countries could serve as a reference for new researchers and guide them differently. Researchers can also consider emerging trends when determining the focus of their studies.


  • Trends in the appropriateness of oral antibiotic prescriptions dispensed in the United States from 2010 to 2018

    by Mahek Garg, Veena Venugopalan, Scott M. Vouri, Vakaramoko Diaby, Nicole M. Iovine, Debbie L. Wilson, Haesuk Park

    Background: One of the goals established by the United States National Action Plan to Combat Antibiotic‐Resistant Bacteria is to reduce inappropriate outpatient antibiotic prescriptions by 50% by 2020. Recent data on the achievement of this goal is lacking. The objective of our study was to examine recent trends in the appropriateness of oral antibiotic prescriptions dispensed to a commercially insured population in outpatient settings in the United States to quantify the relative trend in inappropriate antibiotic prescribing from 2010 to 2018.Methods: Our cross‐sectional analysis examined oral antibiotic prescriptions dispensed in outpatient settings using the IBM MarketScan Commercial Data from January 2010 to December 2018. Trends in the annual proportion of antibiotic prescriptions classified as appropriate, potentially appropriate, inappropriate, or without any medical visit during a 7 days look‐back period were estimated using multivariable generalized linear models with Poisson distribution adjusting for beneficiaries' demographic and infectious conditions.Results: Approximately 170 million oral antibiotic prescriptions were dispensed to 86 million beneficiaries during 2010 to 2018. The mean age of the study population was 34.5 (±19.1) years, with 58.4% females and 24.6% children. We observed a 12.9% (95% Confidence Interval [CI] = 12.6%–13.2%; p < 0.01) decline in rates of antibiotic use, from 832 to 727 prescriptions per 1000 beneficiaries, from 2010 to 2018. The proportion of prescriptions classified as appropriate increased by 36.7% (95% CI = 36.4%–36.9%; p < 0.01); potentially appropriate prescriptions increased by 9.3% (95% CI = 9.1%–9.4%; p < 0.01); whereas inappropriate prescriptions and those without a medical visit declined by 11.3% (95% CI = 11.2%–11.4%; p < 0.01) and 14.0% (95% CI = 13.9%–14.2%; p < 0.01), respectively. Similar declining trends were observed in use and proportion of inappropriate prescriptions for broad‐spectrum antibiotics. In 2018, amoxicillin and azithromycin were the most common appropriate and inappropriate prescription fills, respectively.Conclusion: Although antibiotic use and inappropriate prescribing declined steadily from 2010 to 2018 in the United States, this study demonstrates that we have not achieved the national goal of reducing inappropriate antibiotic prescribing by 50%.

  • Open Access

    Economic Burden of Medically Attended Respiratory Syncytial Virus Infections Among Privately Insured Children Under 5 Years of Age in the USA

    by Phuong T. Tran, Sabina O. Nduaguba, Yanning Wang, Vakaramoko Diaby, Lynn Finelli, Yoonyoung Choi, Almut G. Winterstein

    Background: The cost of medically attended RSV LRI (lower respiratory infection) is critical in determining the economic value of new RSV immunoprophylaxes. However, most studies have focused on intermittent RSV encounters, not the episode of care that captures the entirety of RSV illness.Methods: We created age‐ and condition‐specific cohorts of children under 5 years of age using MarketScan® data (2015–2019). We contrasted aggregating healthcare costs over RSV‐LRTI episodes to ascertaining costs based on RSV‐specific encounters only. Economic burden was estimated by multiplying costs per encounter or per episode by their respective incidence rates.Results: Average cost was higher per episode than per encounter regardless of settings (inpatient: $28,586 vs. $18,056 and outpatient/ED: $2099 vs. $407 for infants). Across ages, the economic burden was highest for infants and RSV‐LRTI requiring inpatient care, but the burden in outpatient/ED settings was disproportionately higher than costs due to higher incidence rates (for inpatient vs. outpatient episodes: $226,403 vs. $101,269; for inpatient vs. outpatient encounters: $151,878 vs. $38,819 per 1000 infant‐years). For high‐risk children, cost and burden were up to 3–10 times higher, respectively.Conclusions: With a comprehensive stratification by settings and risk condition, the encounter‐ versus episode‐based estimates provide a robust range for policymakers' economic appraisal of new RSV immunoprophylaxes.


  • Association between trajectories of prescription opioid use and risk of opioid use disorder and overdose among US nonmetastatic breast cancer survivors

    by Ching-Yuan Chang, Bobby L. Jones, Juan M. Hincapie-Castillo, Haesuk Park, Coy D. Heldermon, Vakaramoko Diaby, Debbie L. Wilson, Wei-Hsuan Lo-Ciganic

    Purpose To examine the association between prescription opioid use trajectories and risk of opioid use disorder (OUD) or overdose among nonmetastatic breast cancer survivors by treatment type. Methods This retrospective cohort study included female nonmetastatic breast cancer survivors with at least 1 opioid prescription fill in 2010–2019 Surveillance, Epidemiology and End Results linked Medicare data. Opioid mean daily morphine milligram equivalents (MME) calculated within 1.5 years after initiating active breast cancer therapy. Group-based trajectory models identified distinct opioid use trajectory patterns. Risk of time to first OUD/overdose event within 1 year after the trajectory period was calculated for distinct trajectory groups using Cox proportional hazards models. Analyses were stratified by treatment type. Results Four opioid use trajectories were identified for each treatment group. For 38,030 survivors with systemic endocrine therapy, 3 trajectories were associated with increased OUD/overdose risk compared with early discontinuation: minimal dose (< 5 MME; adjusted hazard ratio [aHR] = 1.73 [95% CI 1.43–2.09]), very low dose (5–25 MME; 2.67 [2.05–3.48]), and moderate dose (51–90 MME; 6.20 [4.69–8.19]). For 9477 survivors with adjuvant chemotherapy, low-dose opioid use was associated with higher OUD/overdose risk (aHR = 7.33 [95% CI 2.52–21.31]) compared with early discontinuation. For 3513 survivors with neoadjuvant chemotherapy, the differences in OUD/OD risks across the 4 trajectories were not significant. Conclusions Among Medicare nonmetastatic breast cancer survivors receiving systemic endocrine therapy or adjuvant chemotherapy, compared with early discontinuation, low-dose or moderate-dose opioid use were associated with six- to sevenfold higher OUD/overdose risk. Breast cancer survivors at high-risk of OUD/overdose may benefit from targeted interventions (e.g., pain clinic referral).


  • An Umbrella Review of the Cost Effectiveness of Human Papillomavirus Vaccines

    by Phuong T. Tran, Munaza Riaz, Ziyan Chen, Cong Bang Truong, Vakaramoko Diaby

    Background and Objectives Although many systematic reviews for the human papillomavirus vaccines cost effectiveness have been published, they vary in perspectives, methods, and quality. We aimed to condense systematically such evidence to facilitate locating, processing, and learning, not only about the consensus of findings but also how models were built and their evolution over time and across settings. Methods We conducted an umbrella review of cost-effectiveness studies for human papillomavirus vaccines using three databases (PubMed, Embase, and Cochrane). Based on their objectives, we classified studies into three groups (human papillomavirus vaccines cost effectiveness, model characteristics, and all-type vaccines, including human papillomavirus vaccines). We used the AMTAR2 to assess the quality of the studies. Additionally, we provided a summary of study findings, discussions, and evidence gaps in the literature. Results Though most studies were critically low quality and had a low quality of reporting, the human papillomavirus vaccine was consistently cost effective in young girls and men who have sex with men. Stratified analyses by rated quality did not change the results. The quality assessment of the reviews did not necessarily reflect the quality assessment of underlying studies. The human papillomavirus vaccine models became more complex over time, capturing more realistic disease transmission with different human papillomavirus strains and herd immunities. Conclusions Additional evidence is needed for vulnerable populations (e.g., childhood cancer survivors) who are at high risk for human papillomavirus vaccine-related cancers and, therefore, may be more cost effective when receiving human papillomavirus vaccines. Quantifying human papillomavirus vaccine cost effectiveness via meta-analyses is feasible if investigators can increase the homogeneity of their populations.


  • Real-world economic evaluation of prospective rapid whole-genome sequencing compared to a matched retrospective cohort of critically ill pediatric patients in the United States

    by Vakaramoko Diaby, Aram Babcock, Yushi Huang, Richard K. Moussa, Paula S. Espinal, Michelin Janvier, Diana Soler, Apeksha Gupta, Parul Jayakar, Magaly Diaz-Barbosa, et al.

    There is an increasing demand for supporting the adoption of rapid whole-genome sequencing (rWGS) by demonstrating its real-world value. We aimed to assess the cost-effectiveness of rWGS in critically ill pediatric patients with diseases of unknown cause. Data were collected prospectively of patients admitted to the Nicklaus Children’s Hospital’s intensive care units from March 2018 to September 2020, with rWGS (N = 65). Comparative data were collected in a matched retrospective cohort with standard diagnostic genetic testing. We determined total costs, diagnostic yield (DY), and incremental cost-effectiveness ratio (ICER) adjusted for selection bias and right censoring. Sensitivity analyses explored the robustness of ICER through bootstrapping. rWGS resulted in a diagnosis in 39.8% while standard testing in 13.5% (p = 0.026). rWGS resulted in a mean saving per person of $100,440 (SE = 26,497, p < 0.001) and a total of $6.53 M for 65 patients. rWGS in critically ill pediatric patients is cost-effective, cost-saving, shortens diagnostic odyssey, and triples the DY of traditional approaches.


  • Comparative cost-effectiveness of radiotherapy among older women with hormone receptor positive early-stage breast cancer

    by Askal Ayalew Ali, Rima Tawk, Hong Xiao, Anastasia Semykina, Alberto J. Montero, Richard K. Moussa, Olayiwola Popoola, Vakaramoko Diaby

    : The aim was to examine the real-world cost-effectiveness of breast-conserving surgery (BCS) plus hormonal therapy with radiotherapy compared to hormonal therapy alone among women 66 and older wit...


  • Open Access

    Patient Preferences for Early Diagnosis of Endometriosis and Associated Determinants in the United States: A Discrete Choice Experiment

    by Carmen Lyttle-Nguessan, Vakaramoko Diaby

    Background: Endometriosis is a chronic and incurable gynecological disease that mainly affects women of reproductive age worldwide. It imposes clinical and economic burdens on patients, families, and society. A better understanding of the determinants of preferences towards early diagnosis of endometriosis may help develop programs and interventions to reduce the risk of more severe illness. We quantified patient preferences for early endometriosis diagnosis and explored whether preferences vary on the patient characteristics and pre-established social determinants of health. Methods: A discrete choice experiment (DCE) was designed to elicit women's preferences and willingness to pay for early diagnosis of endometriosis. Women ages 18 and older were eligible to participate in the study. The attributes (and levels) considered to describe hypothetical scenarios included diagnosis (immediate/postponed), the chance of advanced endometriosis and more severe illness (low/ high), time away from living, and professional activities (8 days, 15 days, 22 days and 30 days), and possible out-of pocket costs ($0, $15, $60 and $210). The effects of participants' characteristics and social determinants of health on the preference for early diagnosis were modeled using a Tobit model. Results: A total of 66 women with (2) or at-risk (64) of endometriosis completed the experiment. The respondents' age and insurance statuses significantly influenced their preference or choice for early diagnosis. On average, respondents were willing to give up $61.55 out-of-pocket cost to have a low risk of advanced endometriosis and more severe disease. The Tobit model indicates only age and insurance variables significantly affected early diagnosis preference. The results suggest that older ages and not having insurance increase the likelihood of respondents choosing early diagnosis than the younger age group and having insurance. Conclusions: This study indicates the importance of considering the patient characteristics and social determinants of health when designing and implementing health programs and interventions for endometriosis.